Background. Although current guidelines advocate early integration of palliative care, symptom burden and palliative care needs of patients at diagnosis of incurable cancer and along the disease trajectory are understudied. Material and Methods. We assessed distress, symptom burden, quality of life, and supportive care needs in patients with newly diagnosed incurable cancer in a prospective longitudinal observational multicentre study. Patients were evaluated using validated self-report measures (NCCN Distress Thermometer (DT), FACT, SEIQoL-Q, PHQ-4, modified SCNS-SF-34) at baseline (T0), at three (T1), six (T2), and twelve months (T3) follow-up. Results. From 10/2014 to 10/2016, 500 patients (219 women, 281 men; mean age 64.2 years) were recruited at 20 study sites in Germany following diagnosis of incurable metastatic , locally advanced, or recurrent lung (217), gastrointestinal (156), head and neck (55), gynecological (57) and skin (15) cancer. Patients reported significant distress (DT score ≥5) after diagnosis, which significantly decreased over time (T0: 67.2%, T1: 51.7%, T2: 47.9%, T3: 48.7%). The spectrum of reported symptoms was broad with considerable variety between and within the cancer groups. Anxiety and depressiveness were most prevalent early in the disease course (T0: 30.8%, T1: 20.1%, T2: 14.7%, T3: 16.9%). The number of patients reporting unmet supportive care needs decreased over time (T0: 71.8 %, T1: 61.6%, T2: 58.1%, T3: 55.3%). Conclusion. Our study confirms a variable and mostly high symptom burden at the time of diagnosis of incurable cancer, suggesting early screening by using standardized tools, and underlining the usefulness of early palliative care. Implication for practice. A better understanding of symptom burden and palliative care needs of patients with newly diagnosed incurable cancer may guide clinical practice and help to improve the quality of palliative care services. Our study results provide important information for establishing palliative care programs and related guidelines. Distress, symptom burden and the need for support vary, and are often high at the time of diagnosis. These findings underscore the need for implementation of symptom screening

<b><i>Background:</i></b> Little is known on symptom burden, psychosocial needs, and perception of prognosis in advanced lung cancer patients at the time of diagnosis, although early assessment is strongly recommended within the setting of daily routine care. <b><i>Methods:</i></b> Twelve study sites cross-sectionally assessed symptoms and psychosocial needs of patients suffering from newly diagnosed incurable lung cancer. Assessment comprised NCCN distress thermometer, FACT-L, SEIQoL-Q, PHQ-4, and shortened and modified SCNS-SF-34 questionnaires. Additional prognostic information from both patients and physicians were collected. <b><i>Results:</i></b> A total of 208 patients were evaluated. Mean age was 63.6 years, 58% were male, 84% suffered from stage IV lung cancer, and 71% had an ECOG performance status of 0–1. Mean distress level was 5.4 (SD 2.5), FACT-L total score was 86 (21.5), and TOI 50.5 (14.9). PHQ-4 was 4.6 (3.3), and shortened and modified SCNS-SF-34 showed 9 (8.7) unmet needs per patient. According to their physicians’ perspective, 98.1% of patients were reflecting on and 85.2% were accepting incurability, while 26.5% of patients considered the treatment to be of curative intent. <b><i>Conclusion:</i></b> Our findings emphasize substantial domains of symptom burden seen in newly diagnosed, incurable lung cancer patients. Oncologists should be aware of these features and address prognostic issues early in the disease trajectory to facilitate opportunities to improve coping, advance care planning, and appropriate integration of palliative care, thus improving quality of life.

No abstract

Purpose The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA). Methods In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL. Results Two hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA. Conclusion Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.

Background: Refractory malignant ascites in extensive carcinomatous peritonitis presents a major problem in oncology, especially in patients with extensive tumor dissemination and final-stage cancer. Patients near death require treatment that is effective while providing major palliative benefits, and that is something neither paracentesis nor chemotherapy can offer. Patients and Methods: Recombinant human tumor necrosis factor (rhuTNF, Knoll AG, Ludwigshafen) was given to 13 female patients with refractory malignant ascites and imminently terminal cancer. The substance was administered 33 times in total by the intraperitoneal (i.p.) route. Depending on response and general condition the patients were treated 2 or 3 times at weekly intervals at a dose of 0.08 mg/m2 of body-surface area.Results: Regeneration of ascites stopped in all cases. As expected, a significant life-prolonging effect was not achieved. Side effects were kept at a minimum by taking careful account of the condition of each individual patient and administering co-medication accordingly. Conclusion: Intraperitoneal infusion of rhuTNF can help to control ascites in carcinomatous peritonitis patients while causing almost no side effects, thus providing comfort for incurably ill patients.